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Atypical cutaneous leishmaniasis (ACL) has become progressively more frequent in Corte
de Pedra, Northeast Brazil. Herein we characterize clinical presentation, antimony
response, cytokine production and parasite strains prevailing in ACL.
Methodology/Principal Findings
Between 2005 and 2012, 51 ACL (cases) and 51 temporally matched cutaneous leishmania-
sis (CL) subjects (controls) were enrolled and followed over time in Corte de Pedra. Clinical
and therapeutic data were recorded for all subjects. Cytokine secretion by patients’ peripheral
blood mononuclear cells (PBMC) stimulated with soluble parasite antigen in vitro, and geno-
types in a 600 base-pair locus in chromosome 28 (CHR28/425451) of the infecting L. (V.) bra-
ziliensis were compared between the two groups. ACL presented significantly more lesions in
head and neck, and higher rate of antimony failure than CL. Cytosine–Adenine substitutions
at CHR28/425451 positions 254 and 321 were highly associated with ACL (p<0.0001). In vitro
stimulated ACL PBMCs produced lower levels of IFN-γ (p = 0.0002) and TNF (p <0.0001),
and higher levels of IL-10 (p = 0.0006) and IL-17 (p = 0.0008) than CL PBMCs.
Conclusions/Significance
ACL found in Northeast Brazil is caused by distinct genotypes of L. (V.) braziliensis and
presents a cytokine profile that departs from that in classical CL patients. We think that
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differences in antigenic contents among parasites may be in part responsible for the varia-
tion in cytokine responses and possibly immunopathology between CL and ACL.
Author Summary
Leishmania braziliensis is the main cause leishmaniasis that affects skin and upper airways
mucosa in Brazil. Atypical cutaneous leishmaniasis (ACL) presentations are difficult to
diagnose and treat, and do not fit the classical descriptions of the disease. It is not clear
whether ACL share unique features or which are its determinants. In our research we
found that ACL occur in the vicinity of the more common localized cutaneous leishmania-
sis (CL) patients in the study region, so individuals are equally exposed to risks of acquir-
ing either disease.We also found that L. braziliensis from ACL share genetic traits not
commonly identified among parasites from CL, so parasite strain is one plausible risk fac-
tor for ACL. Finally, blood cells from ACL produced levels of immune proteins known to
participate in the pathogenesis of leishmaniasis that were distinct from those of CL
patients. We conclude that atypical cutaneous leishmaniasis in Northeast Brazil may be
considered a clinical presentation per se, in part resulting from infection of human beings
with distinct strains of L. braziliensis. Precise identification of ACL is important because it
usually does not respond to drugs commonly used to treat leishmaniasis in Brazil, but
readily responds to other treatment options available.
Introduction
Tegumentary leishmaniasis is caused by protozoa of the genus Leishmania and presents a
worldwide incidence of 0.7 to 1.2 million cases per year. Brazil, Colombia, Peru, Costa Rica,
Algeria, North Sudan, Ethiopia, Syria, Iran and Afghanistan account for approximately 75% of
the global incidence of disease [1]. In the NewWorld, Leishmania (Viannia) braziliensis is the
predominant species causing American tegumentary leishmaniasis (ATL) [2]. There are four
distinct forms of ATL recognized in Brazil: localized cutaneous leishmaniasis (CL), mucosal
leishmaniasis (ML), disseminated leishmaniasis (DL) and diffuse cutaneous leishmaniasis
(DCL).
The clinical, pathologic and immunologic features of the different types of ATL are distinct
[3]. CL is the most prevalent form and is characterized by one or few ulcers with elevated bor-
ders, occurringmainly in exposed areas of the patients' bodies, like upper limbs, lower limbs,
and face [3]. CL often presents with markedly enlarged lymph nodes, once termed “bubonic
leishmaniasis” [4]. Mildly sore lymphadenopathy usually develops early during infection before
cutaneous lesion fully develops. It affects locally draining nodes, and recedes during treatment,
frequently preceding ulcer healing.
ML affects primarily the nasal mucosa, and is documented in approximately 3% of patients
with history of CL [5, 6]. In the past, ML accounted for up to 24% of ATL in the region of
Corte de Pedra [7]. The remarkable drop in its incidencemay have been caused by a combina-
tion of factors like improvement of local population´s access to early diagnosis and treatment
of ATL, or changes in the human and / or parasite populations in the area. DL presents with
more than ten, and sometimes with several hundred acneiform, papular and ulcerated lesions
spread onto at least two non-contiguous areas of the patients' body surfaces [8–10]. DCL is
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characterized by infiltrated, nodular and non-ulcerated lesions often affecting face, limbs and
trunk of patients [11].
Several reports have called attention to atypical cutaneous leishmaniasis (ACL), which con-
sists in a form of ATL that does not fit into any of the four disease definitions above. Authors
have referred to ACL cases as sporotrichoid [12], erysipeloid [13], recidiva cutis [14] or zosteri-
form [15]. We previously described the clinical features of ACL in an area hyperendemic for L.
(V.) braziliensis transmission in the Northeast of Brazil. In that study, ACL accounted for 1.9%
of all ATL diagnosed at the leishmaniasis clinic that serves as reference for diagnosis and treat-
ment of the disease in the region of Corte de Pedra [16].
Unusual clinical presentations of leishmaniasis have been attributed to a range of possible
causes including host immunosuppression, co-morbidities and pregnancy, as well as environ-
ment factors and strain of the parasite [12–15, 17]. The majority of such patients do not present
with clinical co-morbidities or HIV infection, and are not using immunosuppressive drugs
[18]. Thus other explanations must be sought to address the diversity of disease forms.
Studies of parasite genomic DNA have led us to conclude that the L. (V.) braziliensis popu-
lation in Corte de Pedra is complex, and that different parasite strains are associated with dis-
tinct clinical presentations of disease [19, 20]. More recently, we described a locus starting at
position 425,451 on chromosome 28 of L. (V.) braziliensis (locus CHR28/425451) that is poly-
morphic among strains of the parasite in the region [19]. We found that certain haplotypes of
single-nucleotide polymorphisms (SNP) and insertions-deletions (indel) in CHR28/425451 are
associated with increased risk ratios of DL in that sample [19]. Of note, DL itself was consid-
ered an atypical manifestation of ATL in the past, but it has steadily increased in prevalence
over the decades, reaching a consistent fraction of 4.0% of all ATL in Corte de Pedra [8–10].
In the current study we evaluated the association between SNPs found in the locus CHR28/
425451 of L. (V.) braziliensis and disease outcome, to address whether differences in parasite
strain may be one determinant leading to ACL in Corte de Pedra. We also evaluated whether
such patients might share a common immune profile, comparing the secretion of a panel of
cytokines between immune cells of ACL and CL stimulated with L. (V.) braziliensis antigen in
vitro. Our data showed that ACL found in the northeast of Brazil is caused by genotypically
distinct strains of L. (V.) braziliensis and presents a cytokine profile that departs from that
found in classical CL.
Methods
Study area
Corte de Pedra is composed of 20 municipalities in a rural area located in the southeastern
region of the state of Bahia, in the northeast of Brazil. Corte de Pedra falls within the geo-
graphic coordinates (latitude / longitude) 14°/39°, 13°/39°, 14°/40°, 13°/40°. Lutzomyia (Nysso-
myia) whitmany and Lu. (N.) intermedia are the main vectors transmitting L. (V.) braziliensis
in Corte de Pedra. The leishmaniasis clinic of the Health Post Dr. Jackson Costa serves as refer-
ence for the diagnosis and treatment of ATL in the region. Residents of this area work mostly
in agriculture, which is often carried out in primary or secondary forests.
Patients
Fifty-one patients diagnosedwith ACL in the leishmaniasis clinic at the Health Post between
January 2005 and July 2012 were included in the study. This corresponded to the total ACL
diagnosed in the study period.An equal number of CL subjects were randomly recruited,
matched for the date of initial evaluation at the Health Post leishmaniasis clinic, to serve as
control group. ACL was defined by the presence of unusual cutaneous crusted, lupoid,
Atypical Disease by L. braziliensis
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sporotrichoid, vegetative, verrucous, or zoster-like lesions due to L. (V.) braziliensis. CL was
defined as a single skin ulcer without patients' upper airway or digestive mucosal involvement.
The initial screening diagnosis of ATL was based on parasite isolation in culture of lesion speci-
mens and / or a positive leishmania skin test combined with compatible histopathological find-
ings. All suspectedATL cases had the diagnosis confirmed and Leishmania species determined
by qPCR, using DNA from tissue fragments of lesions.
Relevant clinical data such as the presence of co-morbidities or the use of immunosuppres-
sive drugs that could affect the immune responses and ATL outcomes were investigated in all
patients. Blood tests to determine levels of glucose, urea nitrogen and hepatic enzymes were
performed, as well as serological tests for HIV, hepatitis B virus (HBV), hepatitis C virus
(HCV) and human T-cell lymphotropic virus type 1 (HTLV-1).
ATL treatment
Patients were treated with intravenous pentavalent antimony (Glucantime) at a dose of 20mg/
kg/day for 20 days for individuals with CL, and 30 days for those with ACL. Patients refractory
to antimony were further treated with Glucantime plus Pentoxifylline (400mg, 3 times daily for
20 days), or with amphotericin B (0.5 mg / kg body weight, 3 times per week until reaching a
total dose of 1.0 g to 1.5 g). Failure of antimony therapy was defined as the persistence of active
lesions after two full courses with Glucantime.
Mapping CL and ACL in Corte de Pedra
High-resolution distribution of CL and ACL cases was determined by acquisition of geographic
coordinates using the GPS device Garmin GSX 60 (Garmin, Riverton,WY, USA). Because L.
(V.) braziliensis is believed to be transmitted mostly within plantations where residents of the
region live and work, patient residences were used as reference points for standardization pur-
poses. Collecteddata were statistically compared as describedbelow, and plotted for visual
inspection onto a high-definition satellite photograph of Corte de Pedra (ENGESAT, Curitiba,
Brazil), using ArcGis version 10 (Environmental Systems Research Institute Inc., Redlands,
CA, USA).
Parasites
The L. (V.) braziliensis isolates used in the present study were cultured from aspirates of the
borders of skin lesions. Aspirated material was immediately suspended in biphasic liver infu-
sion tryptose/Novy, McNeal, Nicolle (LIT/NNN)medium and incubated at 26°C for one to
two weeks. The suspension was then transferred to complete Schneider’s medium supple-
mented with 10% heat-inactivated fetal calf serum and Gentamicin 50 mg/mL (Sigma-
Aldrich), and incubated at 26°C for up to another two weeks.We were able to successfully iso-
late L. (V.) braziliensis from 16 ACL and 38 CL patients. Parasites were frozen without further
subculture in 10% DMSO, 90% growth medium in liquid nitrogen, and thawed prior to DNA
extraction for species and genotype determination.
L. (V.) braziliensis genomic DNA extraction and parasite species
determination by PCR
Genomic DNA was extracted from suspensions containing approximately 106 promastigotes
as previously described [19, 20] then re-suspended in 100μL of TE (Tris-HCl 10mM, EDTA
1mM pH 8.0) buffer. Long-term storage DNA aliquots were kept at –70°C, while test samples
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were maintained at –20°C until used. Leishmania species was determined by a serial real-time
quantitative PCR assay system [21].
Genotyping L. (V.) braziliensis from CL and ACL patients
Parasites were genotyped according to the haplotypes of polymorphic nucleotides in the locus
CHR28/425451, previously shown to distinguish L. (V.) braziliensis strains in Corte de Pedra
[19]. Primers 5´:TAAGGTGAACAAGAAGAATC and 5´:CTGCTCGCTTGCTTTC were
used to amplify a 622 nucleotide-long segment in CHR28/425451 from parasite genomic DNA
as previously described [19]. Amplicons were cloned using the Original TA Cloning Kit pCR
2.1 VECTOR (Invitrogen, Thermo Fisher Scientific Co., MA, USA), according to manufactur-
er’s instructions. Briefly, the amplicons were inserted by overnight ligation into PCR 2.1 plas-
mids, which were used for chemical transformation of competent DH5α Escherichia coli.
Plasmid minipreps were generated from four recombinant bacteria colonies per study isolate
[22]. Amplicon cloning was confirmed by digestion analysis, using Eco RI restriction endonu-
clease (Invitrogen).
Plasmid inserts were sequenced by the Sanger method with primers complementary to the
M13 vector sequences. Sequencingwas performed at Macrogen Inc. (Seoul, South Korea).
Mega 5.0 software [23] was used to align the sequences with the CHR28/425451 clones
obtained from the panel of L. (V.) braziliensis parasites, in order to determine the SNP/indel
haplotypes detectable in each study isolate.
Peripheral blood mononuclear cells (PBMC) separation and cytokine
production upon stimulation with L. (V.) braziliensis antigen in vitro
Blood collection for cytokine testing was performed at diagnosis before treatment of enrolled
patients was initiated. PBMC from 20 ACL and 20 CL patients were isolated by density gradi-
ent centrifugationwith Ficoll-Hypaque (Sigma, St. Louis, MO, USA). The cells were cultured
in RPMI 1640 medium supplemented with 5% fetal calf serum, 100 U penicillin/mLand 100μg
streptomycin/mL (GIBCOBRL, Grand Island, NY, USA). Briefly 3 × 106 cells/mLwere plated
in 24-well flat bottommicrotiter plates (Falcon, BectonDickinson, Lincoln Park, NJ, USA) and
kept with media alone (unstimulated), or were stimulated with 5 μg/mL of soluble leishmania
antigen (SLA). SLA was prepared from a stock L. (V.) braziliensis isolate derived from a CL
patient of Corte de Pedra. Cell cultures were incubated at 37°C and 5% CO2 for 72 hours, or 96
hours in the case of IL-17 determination. IFN-γ, TNF, IL-10 and IL-17 levels were determined
in supernatants by ELISA (BD Bioscience Pharmingen, San Jose, CA, USA). The results were
expressed in pg/mL.
Statistical analyses
Comparison of clinical data betweenCL and ACL patients employed Fisher’s exact and Mann
Whitney tests in GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Univar-
iate linear regressions were fitted to evaluate the association between disease duration and both
therapeutic failure and cytokines production. Then the association between these variables was
controlled by clinical presentation in a multivariate model. Statistical analyses were performed
using STATA software (version 14.1; StatCorp, College Station, TX, USA). P Values < 0.05
were considered statically significant.
We compared the geographic distribution of CL and ACL in Corte de Pedra using the Cuzick
and Edward’s test in the geostatistical package Clusterseer version 2.2.4 (Terraseer Inc., Ann
Arbor, MI, USA). This test detects significancewhen two groups of geographic events distribute
differently over the study area. For evaluating the association betweenL. (V.) braziliensis strain
Atypical Disease by L. braziliensis
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and ACL, the distribution frequencies of SNPs and corresponding haplotypes in CHR28/425451
were compared betweenCL and ACL cases by Fisher`s exact test, using GraphPad Prism 5.0
(GraphPad Software, Inc.). All comparisons were considered significant at p<0.05.
Ethical considerations
This study was approved by the Institutional ReviewBoard of the Federal University of Bahia
(document of approval: CAAE– 3041.0.000.054.07).Written consent was obtained from all
participating subjects. All patients whose photographs are shown gave their permission to pub-
lish the pictures after the photographing author (LHG) identified himself and explained the
purpose of the photograph.
Results
Demographic and clinical features of ACL and CL Patients
All patients' biochemical parameters were within normal ranges, and viral serologywas nega-
tive. No patients were using immunosuppressive drugs. Age, gender, clinical manifestations
and response to antimony therapy in study subjects are shown in Table 1. The age and gender
distribution was similar in the 2 groups. Patients with ACL had significantlymore lesions, par-
ticularly above the waist, and in the head and neck regions than those with CL. Atypical lesions
could be classified as vegetative (N = 19), crusted (N = 14), vegetative ulcer (N = 10), verrucous
(N = 3), lupoid (N = 2), sporotrichoid (N = 2) and zoster-like (N = 1) (Fig 1). Disease duration
was significantly longer among ACL individuals (Table 1). Approximately sixty-three percent
of CL patients healed with one course, and ninety-eight percent with up to two courses of anti-
mony (Table 1). In contrast, only approximately thirty-five percent of ACL patients responded
to treatment, including those requiring two courses with Glucantime (Table 1).
The association between disease duration and both therapeutic failure and cytokines pro-
duction (please see cytokine profiles section below) were controlled by clinical presentation in
a multivariate model. No significant association was observed.
L. (V.) braziliensis strains drawn from ACL differ from those obtained of
geographically close CL patients
Geographic coordinates of the residences of ACL and CL patients revealed that both groups of
subjects were widely spread over the affected region (Fig 2), presenting statistically similar
Table 1. Clinical variables compared between 51 atypical (ACL) and 51 localized cutaneous leishmaniasis (CL) temporally matched patients from
Corte de Pedra, Brazil.
ACL CL P
Age [average ± SD] 30.6± 14.4 28.8±9.6 0.68*
Male [N (%)] 38 (74.5) 36(70.6) 0.83#
Illness duration [mean ± SD] 123 ± 249.5 37.2±26.2 0.0006*
Number of lesions [mean ± SD] 41 ± 139 1±0.6 0.0001*
Lesion above waist [N (%)] 43 (84.3) 19(37.3) <0.0001#
Lesion in head and/or neck [N (%)] 26 (51) 5(9.8) <0.0001#
Failure to first antimony treatment [N (%)] 40 (78.4) 19 (37.3) 0.0001#
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distributions in Corte de Pedra (Cusick and Edward's p = 0.258). This suggests the subjects
may be equally exposed to environmental variables that may influence the outcome of ATL.
All patients were infected with L. (V.) braziliensis. In order to evaluate whether different
parasite strains may constitute one risk factor for development of ACL, we compared SNPs at
polymorphic positions in locus CHR28/425451 among L. (V.) braziliensis successfully isolated
from 16 ACL and 38 CL patients. These SNPs defined six haplotypes, according to the nucleo-
tides found at positions 30, 254, 286 and 321 within CHR28/425451 (Table 2). Haplotypes
CCCA, TATA, CACA and TCCA could only be found in parasites from ACL patients, occur-
ring in 10 (62.5%) of these subjects (Table 2). Furthermore, A alleles at positions 254 and
321were highly associated with ACL and could not be detected in parasites drawn from CL
patients (Table 3). These findings indicate that certain strains of L. (V.) braziliensis are more
frequent among patients with atypical lesions.
Cytokine profiles in ACL and CL subjects
Given the notorious role of immune response in the outcomes of ATL, we investigated whether
ACL patients might present an immune profile distinct from that of CL. Exploring a limited
panel of key cytokines, we compared the production of IFN- γ, TNF, IL-10 and IL-17 between
PBMCs from ACL and CL cases, stimulated in vitro with L. (V.) braziliensis antigen (Fig 3).
ACL derived PBMCs consistently produced lower levels of IFN-γ (p = 0.0002) and TNF
Fig 1. Examples of common presentations found among atypical cutaneous leishmaniasis (ACL) patients
in Corte de Pedra region, Northeast Brazil. (A) Crusted, (B) verrucous, (C) lupoid, (D) Zoster-like and (E)
vegetative lesion. Pictures depict actual ACL study subjects. All patients whose photographs are shown gave their
permission to publish the pictures after the photographing author (LHG) identified himself and explained the
purpose of the photograph.
doi:10.1371/journal.pntd.0005100.g001
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(p<0.0001), but higher levels of IL-10 (p = 0.0006) and IL-17 (p = 0.0008) than CL patient
PBMCs. Of note, the limited dispersion in cytokine data, particularly for IFN-γ and TNF, sug-
gests that ACL represents a fairly homogeneous group of individuals, despite the various possi-
ble skin presentations of their disease.
Discussion
Variants of disease caused by L. (V.) braziliensis present diagnostic and therapeutic challenges
even to health care professionals working in regions endemic for CL. Several cases reports of
atypical L. (V.) braziliensis infections have been related to impairment of the immune response
Fig 2. Atypical (ACL) and localized cutaneous leishmaniasis (CL) cases distribute similarly in Corte de
Pedra, Brazil. ACL (N = 51) and temporally matched CL (N = 51) cases diagnosed between 2005 and 2012 in
Corte de Pedra were mapped, and the resulting sets of geographic events were statistically compared. Black dots
and red triangles correspond to ACL and CL patients, respectively. Total number of dots and triangles plotted is
smaller than the actual number of corresponding cases due to overlap of some patients’ geographic coordinates.
The two manifestations of leishmaniasis present similar distributions in Corte de Pedra, with Cuzick and Edward´s
comparison yielding non-significant (p = 0.26). For details refer to Methods section.
doi:10.1371/journal.pntd.0005100.g002
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[16], use of immunosuppressive drugs [17], malnutrition or pregnancy [16, 24]. However, the
majority of ACL do not seem to be related to obvious risk factors [16]. In the current study we
showed that L. (V.) braziliensis strain and levels of inflammatory cytokines are associated with
atypical manifestations of CL.
Subjects with ACL presented to health professionals after a longer duration of illness than
individuals with CL. In this endemic region where self-reporting is common, we hypothesize
that this was due to lack of self-recognitionof the disease because of the atypical presentation.
Typical CL ulcers are usually recognizedby people living in Corte de Pedra, causing most
patients to voluntarily seek care within 30 days of its onset. It is also likely that some of these
individuals reach the reference leishmaniasis clinic at the Health Post after having been seen at
several other facilities in the region, without effective diagnosis of their illness. Also notewor-
thy, ACL lesions were more frequent above the waist and in the face, but such patients did not
present with mucosal involvement. This is in contrast to CL, in which lesions above waist and
in the face indicate patients are at a high risk of developingML [16].
Antimony is the first line drug for CL treatment in Brazil. It is distributed freely by the Brazil-
ianMinistry of Health. However, failure of antimony has been on the rise in the country.
Whereas in the early 80`s only 10% of individuals with CL failed antimony therapy in Brazil [25],
this figure has increased and now ranges from 44 to 53% [26]. A second course of treatment with
antimony usually cures close to 100% of initially refractoryCL patients. In marked contrast, we
observed that more than 60% of ACL failed two courses with antimony (Glucantime).
The main rescue treatment in cases of antimony failure was amphotericin B. Only 5 ACL
cases underwent antimony plus pentoxifylline therapy. These patients tolerated well the treat-
ment, and none of them had to interrupt pentoxifylline use. The only side effect reported was
mild nausea.
Table 2. Comparison of SNP haplotypes frequencies in locus CHR28/425451 between L. (V.) braziliensis isolated from 16 atypical (ACL) and 38
localized cutaneous leishmaniasis (CL) temporally matched patients from Corte de Pedra, Brazil.
Haplotype* (positions are 30,254,286,321) CL ACL P# Odds ratio CI 95%
CCCC 32 10 0.148 0.31 0.08–1.2
TCTC 26 10 0.76 0.77 0.23–2.6
CCCA 0 2 0.084 13.3 0.6–293.7
TATA 0 3 0.008 31.4 1.53–644.2
CACA 0 4 0.006 27.72 1.39–552.0
TCCA 0 1 0.29 7.45 0.287–193.2
* Haplotypes are based on SNP contents at positions 30, 254, 286 and 321 within the locus starting at position 425,451 on the parasite´s chromosome 28.
#Fisher’s exact test.
doi:10.1371/journal.pntd.0005100.t002
Table 3. Comparison of SNP allele frequencies in locus CHR28/425451* between L. (V.) braziliensis isolated from 16 atypical (ACL) and 38 local-
ized cutaneous leishmaniasis (CL) temporally matched patients from Corte de Pedra, Brazil. SNPs in this table correspond to individual SNPs in hap-
lotypes delineated in Table 2.
Position in CHR28/425451 (SNP) CL ACL P# Odds ratio CI 95%
30 (C–T) 26 11 1.0 1.02 0.29–3.58
254 (C–A) 0 7 <0.0001 95.53 5.03–1814
286 (C–T) 26 10 0,76 0.77 0.227–2.61
321 (C–A) 0 10 <0.0001 124.4 6.47–2393
#Fisher’s exact test.
* Locus starts at position 425,451 on the parasite´s chromosome 28.
doi:10.1371/journal.pntd.0005100.t003
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In the OldWorld, genetic diversity among L.major strains has been associated with differ-
ences in the clinical presentation of leishmaniasis [27]. We have previously reported the com-
plexity of L. (V.) braziliensis population in Corte de Pedra, and association between this
complexity and the clinical manifestations of ATL [19, 20]. In those reports we found that DL
was associated with genetically distinct strains of L. (V.) braziliensis [19, 20]. DL has been rap-
idly emerging in Corte de Pedra [10, 28], and like ACL it does not respond well to antimony
therapy. Originally, DL was considered an atypical manifestation of ATL, although due to
increasing frequency, DL can no longer be considered “atypical”. The genotypic differences
identified between isolates in the current study serve to expand our previous documentation
that strain aligns with clinical disease form, indicating that parasite strain may also be a partial
determinant of ACL. It is important to note that alleles found among parasites of ACL cases
could not be found in the CHR28/425451 locus of L. (V.) braziliensis from DL patients diag-
nosed in the region during the study period.
A number of Leishmania genetic loci have been implicated in resistance to antimonial com-
pounds [29, 30]. Recently published field data have indicated that Leishmania (Viannia) spe-
cies naturally infected with Leishmania RNA virus 1 (LRV1) are associated with increased
disease pathology [31–33], and antimony treatment failure in ATL patients of Andean coun-
tries in South America [34]. However, published and preliminary data have not as yet reported
the presence LRV1 within L. (V.) braziliensis strains from eastern Brasil, including the Corte de
Pedra region [35]. Thus, antimonial treatment failures in ACL may arise by mechanisms other
than the presence of LRV1. These interesting questions will be addressed in future studies.
Fig 3. Cytokine levels in supernatants of peripheral blood monuclear cells from atypical (ACL) and
localized cutaneous leishmaniasis (CL) patients stimulated with L. (V.) braziliensis soluble antigen (SLA)
in vitro. Levels of IFN-γ, TNF and IL-10 were determined by ELISA in culture supernatants of PBMCs stimulated
in vitro with SLA for 72 h. Levels of IL-17 were determined after 96 h of stimulation. Data are expressed in pg/mL.
Black and white columns depict average cytokine levels produced by ACL and CL patients, respectively. Bars
denote standard error of the means. All comparisons rendered significant to p<0.001 by Mann Whitney test.
doi:10.1371/journal.pntd.0005100.g003
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The ultimate goal of developingmolecularmarkers of parasite isolates is to eventually utilize
these markers to predict clinical disease outcome, and apply this information for diagnostic
and therapeutic management of ATL. Toward this goal, we examined genotypes of L. (V.) bra-
ziliensis isolates at positions 254 and 321 in CHR28/425451, and found that they segregated
isolates according to form of human disease. The CA haplotype was found only among isolates
from patients with CL, whereas AC was specific for parasites isolated from cases of ACL. It is
possible that diagnostic tools based on PCR-defined genotypes might be developed to detect
whether an ATL patient has been infected with genotypemarking a strain that usually associ-
ates with either ACL or CL, thus putting them at risk for a specific type of diseasemanifestation
[16]. ACL has proven significantlymore refractory to antimony than CL, but fully responsive
to amphotericin B. Thus such information might become of importance for choice of therapy.
In this respect, ACL patients might benefit most if they were preferentially treated with either
amphotericin B or with the combination of antimony and pentoxifylline, avoiding initial ther-
apy with antimony alone.
Classical CL is characterized by a strong type 1 T cell response to Leishmania antigen, with
secretion of high levels of IFN-γ and TNF [36]. Although excessive IFN-γ and cytotoxic CD8+
T cells may contribute to the inflammatory response that leads to ulcer development [37–39],
the importance of IFN-γ as a defense mechanism in CL is well established. Suppressed produc-
tion of IFN-γ is associated with systemic spread of L. infantum and L. donovani [40], and low
IFN-γ is observed in DCL patients infectedwith L. amazonensis [11]. In several disease forms,
the microbicidal effects of IFN-γ are antagonized by IL-10 in vivo [36] or in vitro in macro-
phages [41, 42]. The cytokine responses detected in PBMCs from ACL patients in the current
study were characterized by lower IFN-γ and higher IL-10 than in PBMCs from subjects with
CL.We hypothesize that this imbalancemay favor parasite growth, and may partially explain
the exacerbated pathogenesis of ACL as well as the high rate of therapeutic failure.
The role of IL-17 in the pathogenesis of leishmaniasis has not been completely elucidated.
IL-17 is produced by peripheral blood cells and in lesions of CL patients [43], and IL-17 has
been correlated with pathology in ML [44]. Since IL-17 is negatively regulated by IFN-γ [45],
we can only speculate that the low production of IFN-γwe observed in ACL patients may be
favoring higher IL-17 production, which may be related to an increased tissue inflammation
and the atypical phenotypes of lesions.
We have previously reported that strains of L. (V.) braziliensis that cause DL are genotypi-
cally different from those that cause CL [19]. Herein we further expand that observation to
document distinct genotypes associated with isolates from individuals with ACL. Additionally,
we also found that the profile of key cytokines produced by PBMCs from ACL subjects was
substantially different from those reported for all other manifestations of L. (V.) braziliensis
infection. These findingsmay contribute to our understanding of the pathogenesis of ACL, and
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